In a draft single technology appraisal of the drug, released today, NICE said abatacept is as effective as the other cytokine inhibitor rituximab for RA, but costs twice as much.
Rituximab was recently approved for use with methotrexate in RA patients RA who fail to respond to other disease-modifying anti-rheumatic drugs (DMARDs).
A NICE spokesperson said: ‘Whilst recognizing the severity of the disease, the committee concluded that based on this evidence, abatacept could not be considered good use of NHS resources.’
Chief executive of the National Rheumatoid Arthritis Society Ailsa Bosworth said: ‘To deny patients abatacept is to deny people with a very aggressive and severe form of RA one more chance at controlling the disease and condemn them to a life of pain and disability.’
rachel.liddle@haymarket.com
Comment below and tell us what you think
Telehealth and telecare may help reduce the impact of our ageing population on health, writes Joe Le... Read More
Nurses need to fully understand the provisions of the Mental Capacity Act 2005, writes Georgina Rowl... Read More
Effective prevention of CVD involves a whole 'general practice team approach', writes Jill Ridley. Read More
Contributed by Mr Michael Booker, consultant obstetrician & gynaecologist, and fertility specialist ... Read more
Contributed by Mr David Scott-Coombes, consultant endocrine surgeon at the University Hospital of Wa... Read more
Contributed by Dr David Kernick, a GPSI in headache, based in Exeter. Read more
Pfizer has launched Toviaz (fesoterodine), a once-daily treatment for the symptoms of overactive bla... Read more
Novartis has launched Tasigna (nilotinib), a new antineoplastic agent for Philadelphia chromosome po... Read more
The licence for Ciproxin (ciprofloxacin) has been extended to include the second- and third-line tr... Read more
This site is intended for healthcare professionals only
Comments
Only registered users may comment. Log in now or register for a free account.